A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

550

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic HER2-positive Breast Cancer

Interventions

DRUG: Zanidatamab
DRUG: Trastuzumab
DRUG: Eribulin
DRUG: Vinorelbine
DRUG: Gemcitabine
DRUG: Capecitabine

Sponsor

Jazz Pharmaceuticals